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Abstract 
Currently there is scarce data on endothelial dysfunction (ED) in patients with gout (GA), 
moreover there are no current studies of ED in gout comorbid with arterial hypertension 
(AH). The purpose of this study is to describe specific features of biochemical and 
instrumental markers of endothelial dysfunction in patients with GA comorbid with AH. We 
measured and compared the level of Von Willebrand factor (vWF), interleukin-1beta (IL-1), 
endothelin-1 (ET-1), plasma nitrites (NO2
-
) and nitrates (NO3
-
), the total activity of NO-
synthase, endothelium-dependent (FMD) and endothelium-independent vasodilatation (NMD) 
in 26 patients with GA, 26 patients with AH and in 86 patients with GA+AH. The study 
showed that vWF concentration was highest in comorbidity group (92,9±29,0%) showing no 
significant difference from GA and AH (79,2% and 86,5% respectively). IL-1 was 
highest in GA+AH group (2,0 pg/ml) being significantly higher than in AH (p=0,01) but 
showing no difference from GA (p=1,0). ET-1 concentration was highest in the comorbid 
pathology group (3,07 fmol/ml) versus 1,58 fmol/ml in GA (p<0,0001) and 2,77 fmol/ml in 
AH (p=1,0). NO-synthase activity was greatest in GA and in comorbid pathology groups 
showing no significant intergroup difference; NO2
-
 and NO3
-
 concentrations, being similar in 
these two groups, were statistically higher that in AH. Greatest reduction of FMD and NMD 
was found in comorbid pathology group (5,80% and 10,35% respectively) and it was not 
significantly different from AH group (6,18%; p=0,83 for FMD and 13,59%; p=0,079 for 
NMD). FMD and NMD in gout (10,03% and 15,35% respectively) were similar to normal, 
being significantly different compared to GA+AH group (p=0,045 for FMD and p=0,018 for 
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NMD). This study shows that ED in gout is characterized by significantly higher 
concentration of IL-1, nitric oxide metabolites and intact FMD compared to hypertension. 
Hypertension is characterized by significantly higher concentrations of endothelin-1, more 
prominent increase in von Willebrand factor and significant FMD reduction. Endothelial 
dysfunction in comorbid pathology demonstrates "summation" of pathogenetic mechanisms 
of underlying disorders, expressed in significant increase of interleukin-1 and endothelin-1 
concentrations, hyperactivation of NO synthesis together with decreased FMD and NMD. 
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Introduction 
Currently diseases are considered comorbid when they occur in the same patient and 
have pathogenesis connecting them with each other, which makes such a combination of 
diseases occur more frequently than their possible statistically random coincidence [2, 8]. 
Gout (GA), which is one of the most common rheumatic diseases, has become an 
actual problem in recent decades, but there are only a few works have studied the pathology 
of comorbidity with gout. Thus, in a retrospective study K. Joo et al. [9] found that in the 
Korean population the most common comorbid with gout conditions were hypertension (AH), 
type 2 diabetes mellitus, coronary artery disease, urolithiasis and chronic kidney disease.  
The same argument has been confirmed in the Russian scientists, led by E.I. 
Markelova who showed that in Russian population the most frequent comorbid disorders in 
gout were hypertension (76%), nephrolithiasis (71%), obesity (63%), ischemic heart disease 
(23%), type 2 diabetes (17%) [13]. A retrospective study of the frequency of gout 
comorbidities in he UK and Germany gave slightly different results. So, the most frequently 
encountered were obesity (27,7%), hypertension (17,5%) and diabetes (8,3%) in the UK, and 
in Germany – type 2 diabetes mellitus (25,9%), hypertension (18,5 %) and obesity (13,3%) 
[1]. However, the general conclusion for both countries was the presence of hypertension in 
each 5-6th patient with gout. 
Presented data shows that hypertension is one of the most frequent comorbid diseases 
with gout, which makes this combination of diseases clinically important and requires 
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identification of specific pathogenesis features, in particular, endothelial function, which is 
not investigated enough. 
Interest in endothelial dysfunction (ED) in recent years increases due to the key role of 
this phenomenon in the development of vascular damage of various genesis. The major 
amount of studies traditionally is devoted to stable and unstable forms of coronary artery 
disease, where ED was found to appear as the preclinical manifestation of the disease and as 
secondary changes due to exposure to the major risk factors - smoking, hyperlipidemia, 
hyperglycemia, oxidative stress, etc. 
Research on ED in hypertension includes large number of papers, studying various 
endothelial functions. For example, a 5-year study of 3500 patients with hypertension found a 
significant correlation between reduction of flow-mediated dilation (FMD) and the presence 
of hypertension, as well as with its severity. Interestingly, when evaluating FMD as a 
predictor of hypertension, no significant association was identified. Consequently, FMD is 
considered to be a marker, but not a predictor of hypertension [17]. Some authors have 
reported a decrease in concentrations of nitrate and nitrite in hypertension compared to the 
control group [16], which, in their opinion, may be due to a decrease in eNOS activity or 
accelerated destruction of NO and its free radicals capture. In contrast, a number of studies in 
patients with uncomplicated hypertension, as well as in the presence of left ventricular 
dilatation observed increase in the concentration of nitrates and nitrites [12], accompanied by 
a reduction in their functional efficiency, which was confirmed by a decrease in the level of 
the neurotransmitter cGMP. The authors attribute this phenomenon to the induced 
overproduction of NO-synthase, arising due to the impact of cytokines and oxidative stress 
factors. It is important to note that the increase in the level of NO leads to inhibition of the 
eNOS and promotes pro-inflammatory and toxic effects which further deepen endothelial 
dysfunction [11]. There is no consensus on the role of other ED marker, von Willebrand 
factor (vWF), in hypertension. For example, some studies show its increased concentrations in 
patients with essential hypertension relative to the control group (114 ± 20 IU/dl vs. 90 ± 47 
IU/dl) [15], although there are studies that do not detect such changes in 1st degree 
hypertension [3]. 
Endothelial dysfunction in patients with rheumatologic disorders is even less studied: 
predominantly research is done on rheumatoid arthritis, lupus, ankylosing spondylitis and 
only single works are devoted to gouty arthritis. Rheumatological disorders were also found 
to have changes in markers of endothelial function, but the nature of the changes differed 
from those of cardiovascular disease. Most often, researchers have studied cytokine markers 
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of endothelial function (vWF interleukin-1, endothelin-1), NO-producing function (NO-
synthase, NO2
-
, NO3
-
), vasomotor function (FMD, NMD), however, the data on changes of 
these parameters in patients with gouty arthritis presented by single works. It was found that 
in gout patients increased level of uric acid, which is identified in the nucleus of the 
atherosclerotic plaques [14] indicates the hyperactivation of xanthine oxidase, involved in the 
formation of peroxide oxygen compounds. The study by Cronstein B.N. supposed that  in 
patients with gout, a key role in the chain of ED is given to interleukin-1which in turn causes 
the expression of adhesion molecules and selectins leading to chemotaxis of neutrophils into 
the inflammatory focus. [5] Information about changes in other markers of endothelial 
dysfunction in patients with gout is not found in the literature. Also, there are no in-depth 
study on ED in patients with a combination of gout and hypertension. 
The aim of the study is to reveal features of biochemical and instrumental markers of 
endothelial dysfunction in patients with gout comorbid with arterial hypertension. 
 
Materials and methods 
The study included 138 patients with gout, hypertension and their combination, 
divided into the following groups: I group - 26 patients with gouty arthritis of varying severity 
(without hypertension), II group - 26 patients with hypertension of different severity (without 
gout), group III - 86 patients with gout and hypertension. Control group consisted of 10 
healthy individuals. Clinical characteristics of studied groups is presented in Table 1. 
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Table 1 
Clinical characteristics of studied groups 
Item Group I 
(GA, n=26) 
Group II 
(AH, n=26) 
Group III 
(GA+AH, n=86) 
Age, y 60,8±12,2 58,3±12,0 59,9±12,8 
Sex, m/f 25 (96,2%) /  
1 (3,8%) 
24 (92,3%) /  
2 (7,7%) 
84 (97,7%) /  
2 (2,3%) 
Body weight, kg 92,8 [84,0 – 96,0] 90,0 [82,0 – 96,0] 95,1 [84,0 – 103,0] 
Hypertension duration, y  9,0 [5,0 – 11,0] 9,2 [4,0 – 12,0] 
Gout duration, y 7,0 [3,0 – 10,0]  7,2 [4,0 – 9,0] 
Hypertension grade:    
 1  6 (23,1%) 22 (25,6%) 
 2  15 (57,7%) 40 (46,5%) 
 3  5 (19,2%) 24 (27,9%) 
Gout severity    
Mild 3 (11,5%)  16 (18,6%) 
Moderate 14 (53,9%)  40 (46,5%) 
Severe 9 (34,6%)  30 (34,9%) 
Diabetes mellitus type 2 4 (15,4%) 5 (19,2%) 15 (17,4%) 
Coronary artery disease 8 (30,8%) 9 (34,6%) 28 (32,6%) 
 
All the figures except for age, had a normal distribution and showed no statistically 
significant difference (p> 0,05). 
Von Willebrand factor was determined using biochemical kit "vWF: Ag ELISA" 
(Technoclone, Austria); the level of interleukin-1beta - with the set "Interleukin-1beta-IFA-
BEST" (Vector-Best, Russian Federation), and endothelin-1 was determined using 
biochemical kit "Endothelin 1-21" (Biomedica, Austria), the level of plasma nitrite (NO2
-
, 
mmol/l) was determined by the photometric method using reaction with Griess reagent, the 
level of nitrates (NO3
-
, mmol/l) with cadmium metal recovery method [11, 19], the total 
activity of NO-synthase (NOSx, nmol/min*mg) was determined by evaluating the NADPH2 
oxidation reaction by V. Sumbaev [18]. Determination of endothelium-dependent (FMD) and 
endothelium-independent vasodilatation (NMD) was performed on Aloka SSD-1100 with a 
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7.5 MHz linear probe according to M.C. Corretti modification of standard measurement 
protocol [4]. 
The results of descriptive statistics are presented as mean ± standard deviation (for 
data with a normal distribution), and the median [25 - 75 quartiles] (for data with a 
distribution different from the normal). Testing of all samples for normality was done using 
the Shapiro-Wilk test. Evaluation of the differences between the several groups was 
performed using a parametric Newman-Keuls test or nonparametric Kruskal-Wallis test with 
further comparison using Dunn criterion, qualitative characteristics were compared using the 
chi-squared method. A value of p≤0,05 was considered statistically significant. 
 
Results and discussion 
Comparative analysis of ED parameters in patients of the three study groups identified 
specific characteristics for each of them (see Table 2). Thus, the concentration of the vWF, 
not statistically different between groups (p>0,05) was significantly higher than normal in all 
groups: in patients with GA – 1,5 times higher than normal, in AH – 1,8 times higher, and in 
patients with comorbid pathology - two times higher than the normal values. These changes 
indicate the degree of damage of the vascular endothelium maximally expressed when 
combined damaging factors of GA and hypertension are present, which, in turn, leads to high 
protrombogenic activity of endothelium in this group of patients. This, in our view, may 
explain the higher frequency of severe coronary artery disease, angioplasty and CABG, found 
in an observational study by I.L. Yakimenko in patients with gout comorbid with 
hypertension compared with patients with isolated AH [7]. 
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Table 2 
Markers of endothelial function in patients with gout, hypertension and comorbid pathology 
Item Control group 
(n=10) 
Group I 
(GA, n=26) 
Group II 
(AH, n=26) 
Group III 
(GA+AH, 
n=86) 
p 
I-II 
p  
II-III 
p  
I-III 
vWF, % 47,7 ± 17,7 79,2 ± 35,7 86,5 ± 41,5 92,9 ± 29,0 0,36 0,42 0,2 
Interleukin-1β, 
pg/ml 
0,2 [0,14 – 
0,29] 
1,58 [0,82 – 
2,55] 
0,55 [0,21 – 
2,09] 
2,0 [0,66 – 
5,61] 
0,21 0,01 1,0 
Endothelin-1, 
fmol/ml 
0,339 [0,13 – 
0,45] 
1,58 [1,28 – 
2,02] 
2,77 [2,11 – 
5,03] 
3,07 [2,11 – 
4,32] 
0,0003 1,0 <0,0001 
NO-synthase, 
nmol/min*mg 
1,4 [0,9 – 1,9] 6,0 [3,3 – 10,5] 3,8 [1,2 – 5,6] 5,7 [3,0 – 9,3] 0,10 0,11 1,0 
NO2
-
 ,  
mmol/l 
4,15 [2,94 – 
4,96] 
10,9 [7,9 – 
21,7] 
6,4 [4,3 – 11,3] 9,9 [7,5 – 
26,2] 
0,009 0,005 1,0 
NO3
-
 ,  
mmol/l 
6,93 [5,62 – 
8,29] 
17,5 [13,3 – 
26,6] 
11,0 [5,6 – 
17,6] 
22,1 [13,5 – 
26,0] 
0,03 0,006 1,0 
Brachial artery 
diameter, mm 
3,97 ± 0,28 4,43 ± 0,52 4,54 ± 0,62 4,67 ± 0,55 0,44 0,33 0,19 
FMD,  
% 
11,28 ± 1,98 10,03 ± 6,25 6,18 ± 6,29 5,80 ± 7,83 0,03 0,83 0,045 
NMD, % 20,98 ± 6,01 15,35 ± 7,96 13,59 ± 8,21 10,35 ± 7,26 0,34 0,079 0,018 
 
Analysis of IL-1 concentration in patients of all groups revealed its greatest 
concentration in patients with comorbid pathology. It should be noted that being more 
significantly increased in group with GA (1,58 [0,82 – 2,55] pg/ml) versus AH (0,55 [0,21 – 
2,09] pg/ml) it did not show sufficient statistical difference between them (pI-II = 0,21). 
Moreover, IL-1 levels in hypertension patients were significantly lower compared to patients 
with comorbid disorders (2,0 [0,66 – 5,61] pg/ml, p=0,01), at the same time there was no 
statistical difference in IL-1 levels between GA and comorbid pathology groups (p=1,0). This 
finding can indicate a much larger "contribution" of GA in increased IL-1 concentrations in 
comorbid pathology compared to the "contribution" of hypertension. 
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Different results were obtained analyzing ET-1 in the groups studied. Despite its 
significant increase in all groups, patients with hypertension had statistically higher results 
than the GA group (p=0,0003). The maximum change in this index was observed in the 
comorbid pathology group (3,07 fmol/ml versus 1,58 fmol/ml in GA and 2,77 fmol/ml in 
AH), which lead to its significant difference from the GA group (pI-III<0,0001). Similar data 
was obtained in N.N. Kushnarenko and A.V. Govorina study, which revealed almost two-fold 
significant increaseinET-1 in patients with GA+ AH compared with isolated GA (1,36 
fmol/ml and 0,88 fmol/ml respectively) [10]. This phenomenon, in our opinion, is related to 
the combined damaging effect of arterial hypertension, elevated uric acid and increased IL-1 
concentration. It should be emphasized that the lack of significant difference in ET-1 levels 
between hypertension and comorbid pathology groups (pII-III=1,0) implies a more significant 
contribution of hypertension than gout. 
Comparison of NO-producing function showed a significant but varying degrees of 
increase in all groups studied. Thus, NO-synthase activity was greatest in GA and, 
accordingly, with comorbid pathology without expressing significant difference between the 
groups (pI-III=1,0). At the same time increase in its activity in hypertension was not high 
enough to be statistically different from other groups (pI-II=0,10; pII-III= 0,11). Similarly, the 
least increase in concentration of NO2
-
 and NO3
-
 was found in hypertension, only showing a 
tendency to exceed the reference values, and was significantly lower than those in the GA 
group (pI-II=0,009 and pI-II=0,03 for NO2
-
 and NO3
-
 respectively) and comorbid pathology 
group (pII-III=0,005 and pII-III=0,006 for NO2
-
 and NO3
-
, respectively). Importantly, the 
concentration of NO metabolites in GA and GA+AH groups showed no significant difference 
(pI-III=1,0 for NO2
-
 and NO3
-
), which indicates that gout is a possible cause of iNOS 
hyperactivation and nitrous oxide overproduction and introduces these changes in comorbid 
pathology. 
Artery diameter exceeded normal values in all groups (p=0,01 for groups I and II; 
p=0,001 for group III) and it was the lowest in patients with GA (4,43±0,52 mm), bigger in 
AH group (4,54±0,62 mm), and the highest in GA+AH group (4,67±0,55 mm) with no 
significant intergroup difference (pI-II, pII-III, pI-III>0,05). In our opinion this can be due to the 
greater age category of patients studied (group I – 60,8±12,2 years, group II – 58,3±12,0 
years, group III – 59,9±12,8 years) compared to the age of the reference group (36,0±12,1 
years). Such age-related difference was previously described in other studies and cannot be 
considered specific or diagnostically valuable [4, 6]. 
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Comparative analysis of vasomotor endothelial function also has revealed some 
specific features. So, greatest reduction of FMD and NMD was found in comorbid pathology 
patients and it was not significantly different from the results of AH group (pII-III=0,83 for 
FMD and pII-III=0,079 for NMD). The least changes in vasomotor function were found in GA 
group, where FMD did not significantly differ from control values (p=0,54) and NMD was 
less by 27% only approaching the level of statistical significance (p=0,054). Such a small 
reduction in vascular reactivity in the GA group led to the presence of significant differences 
compared to GA+AH group (pI-III=0,045 for FMD and pI-III=0,018 for NMD) and can be 
regarded as a specific attribute of comorbidity due to a pronounced increase in ET-1 
concentrations in the background of the lack of overproduction NO in patients with 
hypertension. 
 
Conclusions 
 
The data shows that endothelial dysfunction in gout, hypertension and their 
combination has its own characteristics. Thus, gout is characterized by significantly higher 
concentration of IL-1, nitric oxide metabolites and intact FMD compared to hypertension. 
In its turn hypertension compared to gout is accompanied by significantly higher 
concentrations of endothelin-1, a somewhat larger increase in von Willebrand factor and the 
downward trend of NO-synthase activity in the background of slightly increased NO2
-
 and of 
NO3
-
 concentrations, which leads eventually to a significant FMD reduction. 
Endothelial dysfunction in comorbid pathology demonstrates "summation" of 
pathogenetic mechanisms of its formation, expressed in significant increase of IL-1 and 
endothelin-1 concentrations, decreased FMD and NMD, and, consequently, impaired 
vasodilation. 
The findings necessitate further research on endothelial dysfunction and its correction 
at each of the presented pathologies especially the comorbid one where it is most pronounced. 
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